Company Performance - Over the past decade, an investment in Zoetis (ZTS) would have grown by 227%, averaging an annual return of 12.6% [2] - However, the S&P 500 outperformed Zoetis with an average annual gain of 12.7% during the same period [2] - In shorter time frames, Zoetis shares have underperformed, with annual average declines of 18.7%, 4.25%, and 0.43% over the past one, three, and five years respectively [3] Growth Potential - Zoetis has significant growth potential, having been spun off from Pfizer in 2013 and now leading in market share across various animal health segments [4] - The company has made strategic acquisitions to enhance its market position [4] Resilience and Dividends - The company is considered somewhat recession-proof, as animal health care is essential for both livestock and pets [6] - Zoetis offers a dividend yield of 1.3%, with total annual payouts increasing from $0.50 in 2018 to $1.93 per share recently [7] - The current forward-looking price-to-earnings (P/E) ratio of 24 is below the five-year average of 32, suggesting shares may be undervalued [7]